APLLTD - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | APLLTD | Market Cap | 15,551 Cr. | Current Price | 791 ₹ | High / Low | 1,108 ₹ |
| Stock P/E | 35.0 | Book Value | 267 ₹ | Dividend Yield | 1.39 % | ROCE | 11.3 % |
| ROE | 9.68 % | Face Value | 2.00 ₹ | DMA 50 | 827 ₹ | DMA 200 | 902 ₹ |
| Chg in FII Hold | 0.19 % | Chg in DII Hold | -0.13 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 104 Cr. |
| RSI | 45.9 | MACD | -16.9 | Volume | 31,610 | Avg Vol 1Wk | 37,682 |
| Low price | 725 ₹ | High price | 1,108 ₹ | PEG Ratio | -10.6 | Debt to equity | 0.27 |
| 52w Index | 17.2 % | Qtr Profit Var | 15.6 % | EPS | 22.6 ₹ | Industry PE | 28.2 |
📊 Financials: APLLTD shows moderate fundamentals with ROCE at 11.3% and ROE at 9.68%, reflecting average capital efficiency. Quarterly PAT improved from ₹104 Cr. to ₹179 Cr., indicating strong sequential growth. Debt-to-equity at 0.27 is manageable, while EPS of ₹22.6 is modest relative to its market cap of ₹15,551 Cr.
💹 Valuation: The stock trades at a P/E of 35.0, above the industry average of 28.2, suggesting mild overvaluation. P/B ratio is ~2.96 (791/267), which is reasonable. PEG ratio of -10.6 highlights valuation concerns due to inconsistent growth. Dividend yield of 1.39% provides modest income support.
🏢 Business Model & Competitive Advantage: APLLTD operates in pharmaceuticals, focusing on formulations and APIs. Its competitive advantage lies in diversified product offerings and global presence. However, profitability metrics remain weaker compared to peers, limiting shareholder value creation.
📈 Entry Zone: Technicals show RSI at 45.9 (neutral) and MACD negative, with price below DMA 50 & 200. Accumulation may be considered near ₹725–770 for long-term investors. Current valuations are slightly stretched, so cautious entry is recommended.
Positive
- Quarterly PAT growth from ₹104 Cr. to ₹179 Cr.
- Dividend yield of 1.39% adds investor appeal.
- Debt-to-equity ratio of 0.27 indicates manageable leverage.
Limitation
- ROCE (11.3%) and ROE (9.68%) are relatively weak.
- P/E ratio (35.0) above industry average (28.2).
- Negative PEG ratio (-10.6) highlights valuation concerns.
Company Negative News
- Stock trading below DMA 200, reflecting weak momentum.
- DII holdings decreased by -0.13%, showing reduced domestic institutional confidence.
Company Positive News
- FII holdings increased by 0.19%, reflecting foreign investor interest.
- Quarterly PAT growth highlights operational improvement.
Industry
- Pharmaceutical sector benefits from global demand for generics and APIs.
- Industry P/E at 28.2 is lower than APLLTD, showing sector-wide value opportunities.
- Government healthcare initiatives and export demand support long-term growth.
Conclusion
🔎 APLLTD is financially stable with manageable debt and modest dividend yield. While profitability metrics are average and valuations are slightly stretched, the company’s growth momentum and industry tailwinds support long-term potential. Entry near ₹725–770 is attractive for investors seeking steady exposure to the pharmaceutical sector.